H.C. Wainwright raised the firm's price target on Ovid Therapeutics to $4 from $2 and keeps a Buy rating on the shares. The company's OV4071 oral KCC2 candidate is entering the clinic imminently, triggering warrant exercises, the analyst tells investors in a research note. The firm says Ovid has multiple additional potential therapeutic applications slated to be explored with its KCC2 portfolio candidates. H.C. Wainwright cites increased confidence in OV329 for the target doubling.
